MAM
Wunderman Thompson India launches WT Health
Mumbai: Wunderman Thompson India has announced the launch of its healthcare specialist unit Wunderman Thompson Health (WT Health).
Wunderman Thompson India’s new specialized practice offers a unique suite of services which will help health and wellness brands connect more meaningfully with consumers and healthcare professionals (HCPs) across all platforms of communication.
With a multidisciplinary team of more than 100, WT Health has experts across creative, medico legal, compliance and public health; ensuring that technology, creativity and data are drivers of humanizing the healthcare and wellness experience.
Commenting on the launch, Wunderman Thompson South Asia chief executive officer Shamsuddin Jasani said, “We couldn’t have chosen a better time to launch our specialized practice of Wunderman Thompson Health as the healthcare market is poised for exponential growth owing to an unprecedented demand for robust health and wellness solutions. Health and wellness brands are on the lookout for a partner that understands the specific nuances of healthcare marketing, and we believe we can provide business solutions to brands and can unlock growth by leveraging our core strengths of creative, strategy and martech.”
Wunderman Thompson India director – business development Srikant Subramanian commented, “Advances in technology make the next chapter in healthcare delivery very exciting. In the ever evolving, and digitally transforming ecosystem, it’s so important to create tailored communication for each audience, and develop optimized ways to engage with them, be it HCPs, patients, MRs, or pharmacies. Our strategic technology partnerships, leveraged using our in-house medical professionals, allows us to provide truly end-to-end omnichannel healthcare delivery.”
With vast experience across renowned health and wellness brands such as GSK, Zydus Wellness, Sanofi, Unilever, Pfizer, Bayer, Abbott, Mankind, Dr. Reddy’s in several therapy areas such as diabetology, cardiology, pediatrics, Covid care, central nervous system, WT Health will be focused on driving excellence in an evolving healthcare sector and delivering products that are insight driven and innovative to make a positive impact with key stakeholders.
Wunderman Thompson India senior VP and executive business director Samarth Shrivastava added, “It’s an incredibly exciting time to be working in healthcare. Healthcare has evolved massively in the last 19 months compared to the last 19 years. Current developments have forced the industry to evolve at an unprecedented pace and have dramatically accelerated digital health’s adoption. With its pedigree in strategy and its complete suite of services, Wunderman Thompson Health has a unique offering which will help clients achieve their objectives in these dynamic times.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
